Shots:
- Evotec receives $20M as an option fee & is eligible to receive ~$250M as milestones along with royalties. BMS will be responsible for further development & commercialization of a product
- BMS has exercised its option to license Evotec’s EVT8683 after 4.5yrs. of collaboration. Evotec’s iPSC platform allows screening of human iPSC-based disease models at high throughput in combination with unbiased transcriptome analysis
- EVT8683 is a small molecule targeting a key cellular stress response for multiple neurodegenerative indications and is ready to enter clinical development. The candidate was originated from Evotec’s iPSC discovery platform
Click here to read full press release/ article | Ref: Evotec | Image: Wikipedia
The post BMS Exercised Its Option to License Evotec’s EVT8683 for the Treatment of Neurodegenerative Disease first appeared on PharmaShots.
